Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if Isatuximab can alter the immune system in patients
with multiple myeloma or lymphoma upon recovery from the autologous stem cell
transplantation. The investigators will see if Isatuximab makes changes to the immune system
so that upon recovery from the transplant, the immune system can fight the cancer. This study
will have two arms. On one arm (control arm), participants will receive standard transplant
procedures and on the other arm (experimental arm), participants will receive Isatuximab in
addition to the standard transplant procedures. The assignment to these arms is done randomly
(determined by chance, like flipping a coin) by a computer. Each participant will have about
66% chance of getting on the experimental arm and about 33% chance of getting on the control
arm.